SPRUCE BIOSCIENCES, INC. (SPRB)
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Spruce Biosciences, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Not yet recruiting
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA)
MPS IIIB
NCT07579910Enrollment14StartDec 2026est.Primary CompletionAug 2033est.CompletionAug 2033est. - Phase 2Completed
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
SPR001
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
NCT03257462Enrollment24StartJul 2017Primary CompletionMar 2019CompletionMar 2019 - Phase 2Completed
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
SPR001
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia +1
NCT03687242Enrollment11StartSep 2018Primary CompletionJul 2019CompletionAug 2019 - Phase 2Terminated
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Tildacerfont/Placebo
Congenital Adrenal Hyperplasia
NCT04457336Enrollment96StartAug 2020Primary CompletionFeb 2024CompletionMay 2024 - Phase 2Terminated
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Tildacerfont/Placebo
Congenital Adrenal Hyperplasia
NCT04544410Enrollment100StartFeb 2021Primary CompletionOct 2024CompletionJan 2025 - Phase 2Terminated
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Tildacerfont
Congenital Adrenal Hyperplasia, 21-OHD
NCT05128942Enrollment67StartDec 2021Primary CompletionJan 2025CompletionJan 2025 - Phase 2Terminated
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Tildacerfont, Placebo
Polycystic Ovary Syndrome
NCT05370521Enrollment27StartMay 2022Primary CompletionAug 2023CompletionAug 2023 - Expanded accessAvailable
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA)
Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
NCT07733856Enrollment-Start-Primary Completion-Completion-
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Not yet recruiting | Tralesinidase alfa (TA) | NCT07579910 |
| Phase 2 | Completed | SPR001 | NCT03257462 |
| Phase 2 | Completed | SPR001 | NCT03687242 |
| Phase 2 | Terminated | Tildacerfont/Placebo | NCT04457336 |
| Phase 2 | Terminated | Tildacerfont/Placebo | NCT04544410 |
| Phase 2 | Terminated | Tildacerfont | NCT05128942 |
| Phase 2 | Terminated | Tildacerfont, Placebo | NCT05370521 |
| Expanded access | Available | Tralesinidase alfa (TA) | NCT07733856 |